Overview of contemporary reperfusion strategies in acute ST-elevation myocardial infarction

References

• Davies MJ. The pathophysiology of acute coronary syndromes. Heart 83, 361–266 (2000).
   PubMed Web of Science ®Google Scholar
• DeWood MA, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 303, 897–902 (1980).
   PubMed Web of Science ®Google Scholar
• Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 92, 657–671 (1995).
   PubMed Web of Science ®Google Scholar
• Alderman EL, Corley SD, Fisher LD et al. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J. Am. Coll. Cardiol. 22, 1141–1154 (1993).
   PubMed Web of Science ®Google Scholar
• Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 71, 699–708 (1985).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101, 570–580 (2000).
   PubMed Web of Science ®Google Scholar
• Erbel R, Heusch G. Coronary microembolization. J. Am. Coll. Cardiol. 36, 22–24 (2000).
   Google Scholar
• Neumann FJ, Blasini R, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after placement of coronary stents in acute myocardial infarction. Circulation 98, 2695–2701 (1998).
   PubMed Web of Science ®Google Scholar
• Gibson CM, Ryan KA, Murphy SA et al. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. J. Am. Coll. Cardiol. 34, 974–982 (1999).
   PubMed Web of Science ®Google Scholar
• Gibson MC, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101, 125–130 (2000).
   PubMed Web of Science ®Google Scholar
• Bolognese L, Carrabba N, Parodi G et al. Impact of microvascular dysfunction on left ventricular remodelling and long–term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation 109, 1121–1126 (2004).
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Ardisso D, Betriu A et al. Management of acute myocardial infarction in patients with ST-segment elevation. Eur. Heart J. 24, 28–66 (2003).
   PubMed Web of Science ®Google Scholar
• Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343, 311–322 (1994).
   PubMed Web of Science ®Google Scholar
• Second InternationalStudy of Infarct Survival (ISIS) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2, 349–360 (1988).
   Google Scholar
• Third InternationalStudy of Infarct Survival (ISIS) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339, 753–770 (1992).
   Google Scholar
• The International StudyGroup. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet336, 71–75 (1990).
   Google Scholar
• The GUSTO Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329, 673–682 (1993).
   PubMed Web of Science ®Google Scholar
• Neuhaus KL, Feuerer W, Jeep-Tebbe S et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J. Am. Coll. Cardiol. 14, 1566–1569 (1989).
   PubMed Web of Science ®Google Scholar
• The Global Use of Strategiesto Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N. Engl. J. Med. 337, 1118–1123 (1997).
   Google Scholar
• Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence.International Joint Efficacy Comparison of Thrombolytics. Lancet 345, 329–336 (1995).
   Google Scholar
• The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A Comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N. Engl. J. Med. 337, 1124–1130 (1997).
   Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet354, 716–722 (1999).
   PubMed Web of Science ®Google Scholar
• Tebbe U, Michels R, Adgey J et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. J. Am. Coll. Cardiol.31, 487–493 (1998).
   Google Scholar
• InTIME-II Investigators. Intravenous NPA for the treatment of infarction myocardium early. In TIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur. Heart J. 21, 2005–2013 (2000).
   PubMed Web of Science ®Google Scholar
• Thiemann DR, Coresh J, Schulman SP et al. Lack of benefit of intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation 101, 2239–2246 (2000).
   PubMed Web of Science ®Google Scholar
• Berger AK, Radford MJ, Wang Y et al. Thrombolytic therapy in older patients. J. Am. Coll. Cardiol. 36, 366–374 (2000).
   Google Scholar
• The European MyocardialInfarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N. Engl. J. Med. 329, 383–389 (1993).
   Google Scholar
• White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation 97, 1632–1646 (1998).
   PubMed Web of Science ®Google Scholar
• Morrison LJ, Verbeek PR, McDonald AC et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 283, 2686–2692 (2000).
   PubMed Web of Science ®Google Scholar
• Boersma H, Maas AC, Deckers JW et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348, 771–775 (1996).
   PubMed Web of Science ®Google Scholar
• Berkowitz SD, Granger CB, Pieper KS et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 95, 2508–2516 (1997).
   PubMed Web of Science ®Google Scholar
• Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet 354, 716–722 (1999).
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Barron HV, Armstrong PW et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. A comparison of TNK-tPA and rt-PA. Eur. Heart J. 22, 2253–2261 (2001).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Eikelboom JW, Yusuf S. Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. Lancet 356, 449–454 (2000).
   PubMedGoogle Scholar
• Eikelboom JW, Mehta SR, Pogue J, Yusuf S. Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: intracranial haemorrhage in trials of bolus thrombolytic therapy. JAMA 285, 444–450 (2001).
   Google Scholar
• Antman EM, Giugliano CM, Gibson CM et al. Abciximab facilitates the rate and extent of thrombolysis. Results of Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 99, 2720–2732 (1999).
   PubMed Web of Science ®Google Scholar
• Strategies for PatencyEnhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101, 2788–2794 (2000).
   Google Scholar
• Brener SJ, Adgey JA, Zeymer U et al. Combination low-dose t-PA and eptifibatide for acute myocardial infarction. Final results of the INTRO-AMI study. J. Am. Coll. Cardiol. 39, 377–386 (2002).
   PubMed Web of Science ®Google Scholar
• Antman EM, Louwerenburg HW, Baars HF et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105, 1642–1649 (2002).
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Roe MT, Harrington RA et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction. J. Am. Coll. Cardiol.41, 1251–1260 (2003).
   PubMed Web of Science ®Google Scholar
• Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. The GUSTO V investigators. Lancet 357, 1905–1914 (2001).
   PubMed Web of Science ®Google Scholar
• Assessment of the Safetyand Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet358, 605–613 (2001).
   PubMed Web of Science ®Google Scholar
• Wallentin L. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 Plus randomized trial in acute myocardial infarction. Circulation 108, 135–142 (2003).
   PubMed Web of Science ®Google Scholar
• Topol EJ, George BS, Kereiakes DJ et al. A randomised controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79, 281–286 (1989).
   Google Scholar
• Hsia J, Hamilton WP, Keiman N et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin–Aspirin Reperfusion Trial (HART) Investigators. N. Engl. J. Med.323, 1433–1437 (1990).
   PubMed Web of Science ®Google Scholar
• de Bono D, Simoons ML, Tijssen J et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br. Heart J. 67, 122–128 (1992).
   PubMedGoogle Scholar
• The GUSTO AngiographicInvestigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N. Engl. J. Med.22, 1615–1622 (1993).
   Google Scholar
• Thompson PL, Aylward PE, Federman J et al. A randomised comparison of intravenous heparin with oral aspirin and dipyridmole 24 h after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation 83, 1534–1542 (1991).
   PubMed Web of Science ®Google Scholar
• Giugliano R, McCabe CH, Antman EM et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. The Thrombolysis in Myocardial Infarction (TIMI) Investigators. Am. Heart J. 141, 742–750 (2001).
   PubMedGoogle Scholar
• Ross AM, Molhoek P, Lundergan C et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104, 648–652 (2001).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Dellborg DM, Lindahl B et al. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin. Cardiol. 24, I12–I14 (2001).
   Google Scholar
• Simoons ML, Krzeminska-Pakula M, Alonso A et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur. Heart J. 23, 1282–1290 (2002).
   PubMed Web of Science ®Google Scholar
• Cannon CP, McCabe CH, Henry TD et al. A Pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J. Am. Coll. Cardiol. 23, 993–1003 (1994).
   PubMed Web of Science ®Google Scholar
• Jang IK, Brown DF, Giugliano RP et al. A multicenter randomised study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA. MINT study. J. Am. Coll. Cardiol. 33, 1879–1885 (1999).
   PubMed Web of Science ®Google Scholar
• White HD, Aylward PE, Frey MJ et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 96, 2155–2161 (1997).
   PubMed Web of Science ®Google Scholar
• The Global Use of Strategiesto Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med.335, 775–782 (1996).
   Google Scholar
• Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94, 911–921 (1996).
   PubMed Web of Science ®Google Scholar
• White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised Trial. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Lancet358, 1855–1863 (2001).
   PubMed Web of Science ®Google Scholar
• DeWood MA, Spores J, Hensley GR et al. Coronary arteriographic findings in acute transmural myocardial infarction. Circulation 68, I39–I49 (1983).
   PubMed Web of Science ®Google Scholar
• Rentrop P, Blanke H, Wiegand V et al. Recanalization by catheter of the occluded artery after acute myocardial infarction (transluminal recanalization). Deutsch Med. Wochenschrift 105, 1401–1405 (1979).
   Google Scholar
• Meyer T, Merx W, Schmitz H et al. Percutaneous coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. Circulation 66, 914–916 (1982).
   Google Scholar
• Meyer J, Merx W, Dorr R et al. Successful treatment of acute myocardial infarction shock by combined percutaneous transluminal coronary recanalization (PTCR) and percutaneous transluminal coronary angioplasty (PTCA). Am. Heart J. 103, 132–133 (1982).
   PubMed Web of Science ®Google Scholar
• Bussmann D, Hopf R, Schneider W et al. Direkte rekanalisierung durch transluminale angioplastie beim frischen herzinfarkt. Deutsch Med. Wochenschrift 108, 1383–1386 (1982).
   Google Scholar
• Hartzler GO, Rutherford BD, McConahay DR et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. Am. Heart J. 106, 965–973 (1983).
   PubMed Web of Science ®Google Scholar
• Erbel R, Pop T, Meinertz T et al. Combined medical and mechanical recanalization in acute myocardial infarction. Cathet. Cardiovasc. Diagn. 11, 361–377 (1985).
   Google Scholar
• Erbel R, Pop T, Henrichs KJ et al. Value of percutaneous transluminal coronary angioplasty after thrombolytic therapy: a prospective controlled randomised trial. J. Am. Coll. Cardiol. 8, 485–495 (1986).
   Google Scholar
• Erbel R, Pop T, Diefenbach C et al. Long-term results of thrombolytic therapy with and without percutaneous transluminal coronary angioplasty J. Am. Coll. Cardiol.14, 276–285 (1989).
   Google Scholar
• Simoons ML, Arnold AER, Betriu A et al. Thrombolysis with t-PA in acute myocardial infarction: no beneficial effects of immediate PTCA. Lancet 1, 197–203 (1988).
   PubMed Web of Science ®Google Scholar
• The TIMI Study Group. Comparison of invasive and conservative strategies following intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II Trial. N. Engl. J. Med.320, 618–628 (1989).
   PubMed Web of Science ®Google Scholar
• Topol EJ, Califf RM, George BS et al. A randomised trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N. Engl. J. Med.317, 581–588 (1987).
   PubMed Web of Science ®Google Scholar
• Ellis SG, da Silva ER, Heyndrickx G et al. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 90, 2280–2284 (1994).
   Google Scholar
• Ellis SG, Da Silva ER, Spaulding CM et al. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am. Heart J. 139, 1045–1053 (2000).
   Google Scholar
• O´Neill W, Timmis GC, Bourdillon PD et al. A prospective randomised clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N. Engl. J. Med.314, 812–818 (1986).
   Google Scholar
• Grines CL, Rowne KF, Marco J et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. Primary Angioplasty in Myocardial Infarction Study group. N. Engl. J. Med.328, 673–679 (1993).
   PubMed Web of Science ®Google Scholar
• Gibbons RJ, Holmes DR, Reeder CS et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Group. N. Engl. J. Med. 328, 685–691 (1993).
   PubMed Web of Science ®Google Scholar
• Zijlstra F, de Boer MJ, Hoorntje JC et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N. Engl. J. Med. 328, 680–684 (1993).
   PubMed Web of Science ®Google Scholar
• Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. Primary Coronary Angioplasty vs Thrombolysis Collaboration Group. JAMA 278, 2093–2098 (1997).
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet361, 13–20 (2003).
   PubMed Web of Science ®Google Scholar
• Every NR, Prsons LS, Hlatky M et al. A Comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. For the Myocardial Infarction Triage and Intervention Investigators. N. Engl. J. Med.335, 1253–1260 (1996).
   PubMed Web of Science ®Google Scholar
• De Luca G, Suryapranata H, Zijlstra F et al. Syptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J. Am. Coll. Cardiol. 42, 991–997 (2003).
   PubMed Web of Science ®Google Scholar
• De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation 109, 1223–1225 (2004).
   PubMed Web of Science ®Google Scholar
• Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J. Am. Coll. Cardiol. 31, 1240–1245 (1998).
   Google Scholar
• Magid DJ, Calonge BN, Rumsfeld JS et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 284, 3131–3138 (2000).
   PubMed Web of Science ®Google Scholar
• Zahn R, Schiele R, Schneider S et al. Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary angioplasty? Results from the pooled data of the maximal individual therapy in acute myocardial infarction registry and the myocardial infarction registry. J. Am. Coll. Cardiol.37, 1827–1835 (2001).
   PubMed Web of Science ®Google Scholar
• Canto JG, Every NR, Magid DJ et al. The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N. Engl. J. Med.324, 1572–1580 (2000).
   Google Scholar
• Henriques JPS, Haasdijk AP, Zijlstra F. Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours. Zwolle Myocardial Infarction Study Group. J. Am. Coll. Cardiol. 41, 2138–2142 (2003).
   PubMed Web of Science ®Google Scholar
• Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98, 734–741 (1998).
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after placement of coronary stents following acute myocardial infarction. J. Am. Coll. Cardiol. 35, 915–921 (2000).
   PubMed Web of Science ®Google Scholar
• Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N. Engl. J. Med.344, 1895–1903 (2001).
   PubMed Web of Science ®Google Scholar
• Antoniucci D, Rodriguez A, Hempel A et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J. Am. Coll. Cardiol.42, 1879–1885 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. CADILLAC Investigators. N. Engl. J. Med. 346, 957–966 (2002).
   PubMed Web of Science ®Google Scholar
• Vermeer F, Ophuis AJ, Berg EJ et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 82, 426–431 (1999).
   PubMed Web of Science ®Google Scholar
• Widimsky P, Groch L, Zelizko M et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur. Heart J.21, 823–831 (2000).
   PubMed Web of Science ®Google Scholar
• Widimsky P, Budesinsky T, Vorac D et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: Final results of the randomised national multicentre trial – PRACUE-2. PRAGUE Study Group Investigators. Eur. Heart J.24, 94–104 (2003).
   PubMed Web of Science ®Google Scholar
• Andersen HR, Nielsen TT, Rasmussen K et al. The Danish Multicenter Randomized Trial on Thrombolytic Therapy versus Acute Coronary angioplasty in Acute Myocardial Infarction. DANAMI-2 Investigators. N. Engl. J. Med. 349, 733–742 (2003).
   PubMed Web of Science ®Google Scholar
• Bonnefoy E, Lapostolle F, Leizorovicz A et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. CAPTIM study group. Lancet360, 825–829 (2002).
   PubMed Web of Science ®Google Scholar
• Scheller B, Hennen B, Hammer B et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. SIAM III Study Group. J. Am. Coll. Cardiol. 42, 634–641 (2003).
   PubMed Web of Science ®Google Scholar
• Steg PG, Bonnefoy E, Chabaud S et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty. Circulation 108, 2851–2856 (2003).
   PubMed Web of Science ®Google Scholar
• Zijlstra F. Angioplasty versus thrombolysis for acute myocardial infarction: a quantitative overview of the effects of interhospital transportation. Eur. Heart J.24, 21–23 (2003).
   Google Scholar
• Mehta RH, Criger DA, Granger CB et al. Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. J. Coll. Cardiol.40, 1034–1040 (2002).
   PubMed Web of Science ®Google Scholar
• Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation103, 1809–1814 (2003).
   Google Scholar
• Ross AM, Coyne KS, Reiner JS et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue-angioplasty in acute myocardial infarction: the PACT trial. J. Am. Coll. Cardiol.34, 1954–1962 (1999).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Schlotterbeck K et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 291, 947–954 (2004).
   PubMed Web of Science ®Google Scholar